Platforms RNA/mRNA Medicine Platforms in Rare Diseases and Vaccines Partnership Platform Program Partner Indication Status LUNAR®-GSDIII Glycogen Storage Disease Type III Phase 1/2 * LUNAR®-RARE Undisclosed Rare Disease Preclinical LUNAR®-HBV Hepatitus B Virus (HBV) Preclinical LUNAR®-NASH Nonalcholic Steatohepatitis (NASH) Preclinical $1B+ in Potential Milestones & Royalties We have partnered with a number of industry leaders and have a robust and diverse preclinical and clinical drug development pipeline. Our external development partners include Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Takeda Pharmaceutical Company Limited, CureVac AG and Synthetic Genomics, Inc. * https://clinicaltrials.gov/ct2/show/NCT04574830 LUNAR®-GSDIII Arcturus has partnered with Ultragenyx to develop messenger RNA (mRNA) therapeutic candidates for certain rare disease targets. The first disclosed indication is Glycogen Storage Disease Type III. Learn More LUNAR®-HBV Arcturus has partnered with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop nucleic acid medicines for the treatment of hepatitis B virus infection and other diseases. Learn More LUNAR®-NASH Arcturus, in partnership with Takeda Pharmaceutical Company Ltd., is developing RNA medicines for the treatment of nonalcoholic steatohepatitis (NASH) and other gastrointestinal disorders, utilizing our wholly owned therapeutic delivery platform, LUNAR®. Learn More Home Contact Careers Terms and Conditions Privacy Policy © 2021 Arcturus Therapeutics, Inc.